FDA Grants Orphan Drug Status to Cabaletta for Systemic Sclerosis Treatment
Wednesday, 20 March 2024, 15:54
FDA Grants Orphan Drug Status
The Food and Drug Administration has awarded Cabaletta orphan drug status for its systemic sclerosis treatment, a noteworthy achievement for the company.
Support for Drug Development
This designation offers valuable incentives and support for Cabaletta to advance its promising therapy for systemic sclerosis patients.
With the FDA's recognition, Cabaletta is well-positioned to potentially make a positive impact on the lives of individuals affected by this challenging autoimmune disease.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.